About Quantum Pharma Group
Quantum Pharma Group is a Healthcare company based in Durham (United Kingdom) founded in 2004, and was acquired by Clinigen in September 2017. Manufacturer of drugs. Its chief executive, as recorded, is Andrew Matthews. Its focus areas include Traditional Pharmaceuticals.
Company details
Quantum Pharma Group was established in 2004 and is headquartered in Durham, United Kingdom. Operations focus on the manufacturing of pharmaceutical drugs within the healthcare sector. The company is led by Andrew Matthews in the role of CEO and Managing Director. Activities are centered on drug production, with a base in the UK serving regional needs in pharmaceuticals.
- Headquarters Durham, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website quantumpharmagroup.com
- Social LinkedIn X
- Acquired by Clinigen (Sep 2017)
Funding Insights of Quantum Pharma Group
- Total Rounds 1
- Last Round Post-IPO — $18.32M
- First Round $18.32M
(Oct 2016)
All 1 funding rounds of Quantum Pharma Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $18.32M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Quantum Pharma Group
Quantum Pharma Group has secured backing from 1 investor. Prominent investors backing the company include Clinigen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty medicines are supplied via clinical trials and access programs. | 2010 | clinigengroup.com | Burton-on-trent, United Kingdom |
Investor details for Quantum Pharma Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Quantum Pharma Group
1 people are tracked at Quantum Pharma Group (1 in leadership).
| Name | Role | Group |
|---|---|---|
Andrew Matthews | CEO & MD | Leadership |
Complete people profiles for Quantum Pharma Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Quantum Pharma Group
4 dated milestones of Quantum Pharma Group across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Quantum Pharma Group is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $18.3M.
- Exit Acquired by Clinigen.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Quantum Pharma Group
Quantum Pharma Group was founded in 2004 and raised its 1st funding round 12 years after it was founded.
Quantum Pharma Group is headquartered in Durham, United Kingdom.
Andrew Matthews is the CEO of Quantum Pharma Group, as recorded in our data.
Quantum Pharma Group was established in 2004 and is headquartered in Durham, United Kingdom. Operations focus on the manufacturing of pharmaceutical drugs within the healthcare sector. The company is led by Andrew Matthews in the role of CEO and Managing Director. Activities are centered on drug production, with a base in the UK serving regional needs in pharmaceuticals.
Quantum Pharma Group has 1 investor. Key investors include Clinigen.
Yes. Quantum Pharma Group was acquired by Clinigen in September 2017.